2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06C.02 Description of A Single Center Thoracic Rapid Tissue Donation Program Experience

Pdf Summary

The Moffitt Cancer Center's Thoracic Rapid Tissue Donation (RTD) program has been a pivotal initiative in oncology research, specifically for lung cancer post-mortem donations. Since December 2015, 100 patients have consented to this program, with successful tissue and body fluid collections from 58 donors to aid studies on tumor dynamics such as evolution, heterogeneity, and resistance to treatments.<br /><br />The collected samples include 789 formalin-fixed paraffin-embedded (FFPE), 737 snap-frozen, and 235 fresh tissues. These are used for various proteogenomic analyses, such as DNA and RNA sequencing, immunohistochemistry, and mass spectrometry. The median time from patient death to sample collection was 10 hours, enabling high-quality sample preservation for research.<br /><br />The program included patients diagnosed with various lung cancer types: adenocarcinoma (32 donors), squamous cell carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and mesothelioma. Important mutations, including EGFR, KRAS, NRAS, MET exon 14 skipping, and ALK and ROS1 fusions, were identified.<br /><br />A range of lung cancer translational studies is ongoing, leveraging these post-therapy samples to deepen understanding of disease progression and therapeutic resistance. The future expansion of the RTD program aims to include all cancer types, broadening the scope for groundbreaking research.<br /><br />This research is supported by a grant from both Bristol Myers Squibb and Moffitt's Lung Cancer Center of Excellence. Acknowledgments were given to donors and their families for their invaluable contribution to this program, and to the NIH-supported Moffitt Cancer Center's Tissue and Molecular Cores for their logistical support.

Asset Subtitle

Theresa Boyle

Meta Tag

Speaker Theresa Boyle

Topic Pathology & Biomarkers

Keywords

Moffitt Cancer Center

Thoracic Rapid Tissue Donation

lung cancer

tumor dynamics

proteogenomic analyses

DNA sequencing

RNA sequencing

therapeutic resistance

post-mortem donations

Bristol Myers Squibb